CURCUMA AERUGINOSA ROXB. EXTRACT INHIBITS THE PRODUCTION OF PROINFLAMMATORY CYTOKINES ON RAW 264.7 MACROPHAGES

Q2 Pharmacology, Toxicology and Pharmaceutics

International Journal of Applied Pharmaceutics Pub Date : 2024-02-15 DOI:10.22159/ijap.2024.v16s1.08

Irene Puspa Dewi, Dachriyanus, Y. Aldi, Nor Hadiani Ismail, D. Hefni, Meri Susanti, Suryati Syafri, F. Wahyuni

引用次数: 0

Abstract

Objective: The study explores the potential of Curcuma aeruginosa Roxb. extract for anti-inflammatory properties. Methods: Curcuma aeruginosa Roxb. simplicia was macerated with distilled ethanol. In vitro testing was done on Raw 264.7 macrophages to fulfill this aim by observing Tumor Necrosis Factor (TNF)-α, Interleukin (IL)-6 production and phagocytosis activity. The production of IL-6 and TNF-α were determined using the ELISA method while phagocytosis activity using the neutral red uptake method. Results: The results showed that Curcuma aeruginosa Roxb. extract inhibited production of TNF-α and IL-6 and phagocytic activity and on Raw 264.7 macrophages. Conclusion: The results demonstrated that Curcuma aeruginosa Roxb. extract could be developed as an anti-inflammatory, which can be improved as a novel pharmaceutical approach for treating inflammation-related illness.

查看原文本刊更多论文

莪术萃取物抑制生 264.7 巨噬细胞产生促炎细胞因子提取物抑制生 264.7 巨噬细胞产生促炎细胞因子

研究目的本研究探讨了莪术提取物的抗炎潜力。研究方法用蒸馏乙醇浸渍莪术。为了达到这一目的，对 Raw 264.7 巨噬细胞进行了体外测试，观察肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6 的产生和吞噬活性。IL-6和TNF-α的产生采用酶联免疫吸附法测定，吞噬活性采用中性红吸收法测定。结果表明结果表明，莪术提取物能抑制 Raw 264.7 巨噬细胞产生 TNF-α 和 IL-6，并抑制其吞噬活性。结论结果表明，莪术提取物可作为一种抗炎药物进行开发，并可作为治疗炎症相关疾病的一种新型药物方法进行改进。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Applied Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

1.40

自引率

0.00%

发文量

219

期刊介绍： International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.